Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P42695

UPID:
CNDD3_HUMAN

ALTERNATIVE NAMES:
Non-SMC condensin II complex subunit D3

ALTERNATIVE UPACC:
P42695; A6NFS2; Q4KMQ9

BACKGROUND:
The Condensin-2 complex subunit D3, known alternatively as Non-SMC condensin II complex subunit D3, is integral to establishing mitotic chromosome structure and neuronal stem cell chromosome condensation. Its functions include promoting the resolution of double-strand DNA catenanes and decatenation of centromeric ultrafine DNA bridges, which are vital for accurate chromosome segregation and neurogenesis.

THERAPEUTIC SIGNIFICANCE:
The association of Condensin-2 complex subunit D3 with Microcephaly 22, a disease marked by significantly reduced cerebral cortex size, underscores its importance in brain development. Exploring the mechanisms by which Condensin-2 complex subunit D3 influences neurogenesis and chromosome condensation may lead to novel interventions for microcephaly and other cognitive disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.